Medicine · 2016 · 26 citations · 21 references
MedicineOncologyPathologyBreast OncologyMetastasisMolecular OncologyBreast Cancer OncologyBreast Cancer SurgeryBreast PathologyBreast SurgeryLymph Node MetastasisLymph Node PathologyAxillary Lymph Node MetastasisAxillary StagingEstrogen Receptor StatusKi-67 Labeling IndexLymph Node Involvement PrognosisLymph Node MetastasesLymphovascular Invasion PrognosisTumor Differentiation Assessment
The aim of this study was to evaluate the association between pretreatment molecular and clinical factors and axillary lymph node metastases in early breast cancer. A total of 367 consecutive breast cancer patients with cT1-2NxM0 who underwent breast conserving surgery and axillary lymph node dissection followed by whole breast irradiation were enrolled. We evaluated the pathologic tumor and node status, tumor differentiation, calcification, and lymphovascular invasion, the status of estrogen receptor (ER), progesterone receptor (PR), epidermal growth factor receptor 1 (EGFR1), and human epidermal growth factor receptor 2 (HER2), the expression of E-cadherin, P53, and Ki-67 index. Totally, 108 (29.4%) of the 367 patients had positive axillary lymph nodes. An increased tumor size (P = 0.024), the presence of lymphovascular invasion (P < 0.001), and Ki-67 index of >20% (P = 0.038) were significantly associated with axillary lymph node metastases on the multivariate analysis. In our study, 86.2% of the patients with all the unfavorable factors had an involvement of axillary nodal metastases, and only 12.2% of the patients with all the favorable predictors had positive axillary nodes. The predictive power was significant on the receiver operating curve (P < 0.001). We found that several factors, such as tumor size, lymphovascular invasion, and the Ki-67 index, are independent factors that predict positive ALNM on multivariate analysis for the patients with cT1-2 breast cancer. Clinicians simply could predict the probability of ALNM after verifying the molecular and clinical factors in early breast cancer.
21
Dennis J. Slamon, Gary M. Clark, Steven Wong et al. · Science · 1987 · 11.7K citations
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Lisa A. Carey, Elizabeth Claire Dees, Lynda Sawyer et al. · Clinical Cancer Research · 2007 · 2.1K citations · Full text
Medicine, Oncology, Breast Oncology +14
Jennet Harvey, Gary M. Clark, C. Kent Osborne et al. · Journal of Clinical Oncology · 1999 · 2.1K citations
Medicine, Endocrinology, Oncology +17
Robert C. Bast, Peter M. Ravdin, Daniel F. Hayes et al. · Journal of Clinical Oncology · 2001 · 886 citations
Medicine, Oncology, Breast Oncology +15